Last reviewed · How we verify

Bupivacaine + Sufentanil epidural

Charles University, Czech Republic · FDA-approved active Small molecule

Bupivacaine blocks sodium channels to provide local anesthesia, while sufentanil is an opioid agonist that binds to mu receptors to provide analgesia, together delivering epidural anesthesia and pain relief.

Bupivacaine blocks sodium channels to provide local anesthesia, while sufentanil is an opioid agonist that binds to mu receptors to provide analgesia, together delivering epidural anesthesia and pain relief. Used for Epidural anesthesia and analgesia for surgical procedures, Epidural pain management in labor and delivery.

At a glance

Generic nameBupivacaine + Sufentanil epidural
Also known asEpidural analgesia with bupivacaine and sufentanil
SponsorCharles University, Czech Republic
Drug classLocal anesthetic + opioid combination
TargetVoltage-gated sodium channels (bupivacaine); mu opioid receptor (sufentanil)
ModalitySmall molecule
Therapeutic areaAnesthesia and Pain Management
PhaseFDA-approved

Mechanism of action

Bupivacaine is a long-acting local anesthetic that inhibits sodium influx in nerve fibers, preventing action potential propagation and sensory/motor blockade in the epidural space. Sufentanil is a potent synthetic opioid that activates mu opioid receptors in the central and peripheral nervous system, enhancing analgesia. The combination provides synergistic anesthetic and analgesic effects when administered epidurally.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: